Skip to main content
Top
Published in: Pathology & Oncology Research 2/2010

01-06-2010

Chemo-radiotherapy in Locally Advanced Squamous Cell Oesophageal Cancer—are Upper Third Tumours more Responsive?

Authors: Andras Papp, Laszlo Cseke, Robert Farkas, Gabor Pavlovics, Gabor Horvath, Gabor Varga, Andras Szigeti, Szabolcs Bellyei, Sandor Marton, Laszlo Poto, Katalin Kalmar, Andras Vereczkei, Eva Pozsgai, Ors Peter Horvath

Published in: Pathology & Oncology Research | Issue 2/2010

Login to get access

Abstract

Before neoadjuvant therapy was widely applied, the prognosis of oesophageal cancer had been considered dependent on the location of the tumor, i.e. upper third cancers had had the worst prognosis. The aim of this retrolective study was to prove the efficiency of the neoadjuvant treatment, and to compare the response of esophageal cancer in different locations. Between January 1998 and September 2005, 102 patients with locally advanced squamous cell oesophageal cancer received preoperative chemo-radiotherapy. In 40 cases the tumor was located in the upper third and in 62 cases in the middle third of the oesophagus. After a four-week-long treatment free period restaging was carried out and patients considered resectable were submitted to surgery. From 40 patients with upper third oesophageal cancer 28 underwent oesophageal resection or pharyngo-laryngectomy. Thiry-five percent a complete histopathological remission was observed. From 62 patients with middle third oesophageal cancer 43 underwent oesophageal resection. Histological examination of the resected specimens documented complete response only in three patients. The median survival and the R0 resection rate were similar in the two groups. Although the resection rate, perioperative morbidity, mortality and the median survival were similar in the two groups, a significantly higher rate of complete response (p < 0,05) was observed in patients with upper third oesophageal cancer compared to patients with middle third oesophageal cancer. It seems that upper third oesophageal cancer has superior sensitivity to multimodal treatment therefore our results may support that upper third location is not an unfavorable prognostic factor any more.
Literature
1.
go back to reference Lerut T, Coosemans W, Decker G, De Leyn P, Nafteux Ph, Van Raemdonck D (2001) Cancer of the esophagus and gastro-esophageal junction: potentially curative therapies Surg Oncol 10:113–122 Lerut T, Coosemans W, Decker G, De Leyn P, Nafteux Ph, Van Raemdonck D (2001) Cancer of the esophagus and gastro-esophageal junction: potentially curative therapies Surg Oncol 10:113–122
2.
3.
go back to reference Siewert JR, Stein HJ, Feith M, Bruecher BL, Bartels H, Fink U (2001) Histologic tumor type is an independent prognostic parameter in esophageal cancer: lessons from more than 1,000 consecutive resections at a single center in the Western world. Ann Surg. 234(3):360–367 discussion 368–9CrossRefPubMed Siewert JR, Stein HJ, Feith M, Bruecher BL, Bartels H, Fink U (2001) Histologic tumor type is an independent prognostic parameter in esophageal cancer: lessons from more than 1,000 consecutive resections at a single center in the Western world. Ann Surg. 234(3):360–367 discussion 368–9CrossRefPubMed
4.
go back to reference Law S, Kwong DL, Kwok KF, Wong KH, Chu KM, Sham JS, Wong J (2003) Improvement in treatment results and long-term survival of patients with esophageal cancer: impact of chemoradiation and change in treatment strategy. Ann Surg. 238(3):339–347 discussion 347–8PubMed Law S, Kwong DL, Kwok KF, Wong KH, Chu KM, Sham JS, Wong J (2003) Improvement in treatment results and long-term survival of patients with esophageal cancer: impact of chemoradiation and change in treatment strategy. Ann Surg. 238(3):339–347 discussion 347–8PubMed
5.
go back to reference P. Sorrentino et al. (1988) Prognostic Significance of Tumor Stage and Lymph Node Involvement in Thoracic Esophageal Cancer. In: J.R. Siewert, A.H.Hölscher (ed) Diseases of the esophagus Springer-Verlag Berlin Heidelberg, pp:709–713, P. Sorrentino et al. (1988) Prognostic Significance of Tumor Stage and Lymph Node Involvement in Thoracic Esophageal Cancer. In: J.R. Siewert, A.H.Hölscher (ed) Diseases of the esophagus Springer-Verlag Berlin Heidelberg, pp:709–713,
6.
go back to reference Piessen G, Mariette C, Triboulet JP (2005) Cervical and upper-third thoracic oesophageal carcinoma: a single pathological entity? Ann Chir. 130(2):86–91CrossRefPubMed Piessen G, Mariette C, Triboulet JP (2005) Cervical and upper-third thoracic oesophageal carcinoma: a single pathological entity? Ann Chir. 130(2):86–91CrossRefPubMed
7.
go back to reference Feinstein AR (1985) Clinical epidemiology. Saunders, Philadelphia Feinstein AR (1985) Clinical epidemiology. Saunders, Philadelphia
8.
go back to reference Horvath OP, Cseke L, Kalmar K, Varga G, Horvath G (2001) Larynx-preserving pharyngo-esophagectomy after chemoradiation in the treatment of cancer of the pharyngo-esophageal junction. Ann Thorac Surg. 72(6):2146–2147CrossRefPubMed Horvath OP, Cseke L, Kalmar K, Varga G, Horvath G (2001) Larynx-preserving pharyngo-esophagectomy after chemoradiation in the treatment of cancer of the pharyngo-esophageal junction. Ann Thorac Surg. 72(6):2146–2147CrossRefPubMed
9.
go back to reference Pavlovics G, Cseke L, Papp A, Tizedes G, Tabar BA, Horvath PO (2006) Esophagus reconstruction with free jejunal transfer. Microsurgery 26(1):73–77CrossRefPubMed Pavlovics G, Cseke L, Papp A, Tizedes G, Tabar BA, Horvath PO (2006) Esophagus reconstruction with free jejunal transfer. Microsurgery 26(1):73–77CrossRefPubMed
10.
go back to reference Wong R, Malthaner R (2003) Combined chemotherapy and radiotherapy (without surgery) compared with radiotherapy alone in localised carcinoma of the esophagus (Cochrane Review), in the Cochrane Library, Issue 1. Oxford, Update Softwer Wong R, Malthaner R (2003) Combined chemotherapy and radiotherapy (without surgery) compared with radiotherapy alone in localised carcinoma of the esophagus (Cochrane Review), in the Cochrane Library, Issue 1. Oxford, Update Softwer
11.
go back to reference Mariette C, Piessen G, Triboulet JP (2007) Therapeutic strategies in oesophageal carcinoma: role of surgery and other modalities. Lancet Oncol 8:545–553CrossRefPubMed Mariette C, Piessen G, Triboulet JP (2007) Therapeutic strategies in oesophageal carcinoma: role of surgery and other modalities. Lancet Oncol 8:545–553CrossRefPubMed
12.
go back to reference El Nakadi I, Van Laethem JL, Houben JJ, Gay F, Closset J, Van Houtte P, Danhier S, Limbosch JM, Lambilliotte JP, Gelin M (2002) Squamous cell carcinoma of the esophagus: multimodal therapy in locally advanced disease. World J Surg 26(1):72–78CrossRefPubMed El Nakadi I, Van Laethem JL, Houben JJ, Gay F, Closset J, Van Houtte P, Danhier S, Limbosch JM, Lambilliotte JP, Gelin M (2002) Squamous cell carcinoma of the esophagus: multimodal therapy in locally advanced disease. World J Surg 26(1):72–78CrossRefPubMed
13.
go back to reference Meneu-Diaz JC, Blazquez LA, Vicente E, Nuno J, Quijano Y, Lopez-Hervas P, Devesa M, Fresneda V (2000) The role of multimodality therapy for resectable esophageal cancer. Am J Surg 179(6):508–513CrossRefPubMed Meneu-Diaz JC, Blazquez LA, Vicente E, Nuno J, Quijano Y, Lopez-Hervas P, Devesa M, Fresneda V (2000) The role of multimodality therapy for resectable esophageal cancer. Am J Surg 179(6):508–513CrossRefPubMed
14.
go back to reference Bosset JF, Gignoux M, Triboulet JP, Tiret E, Mantion G, Elias D, Lozach P, Ollier JC, Pavy JJ, Mercier M, Sahmoud T (1997) Chemoradiotherapy followed by surgery compared with surgery alone in squamous-cell cancer of the esophagus. N Engl J Med 337(3):161–167CrossRefPubMed Bosset JF, Gignoux M, Triboulet JP, Tiret E, Mantion G, Elias D, Lozach P, Ollier JC, Pavy JJ, Mercier M, Sahmoud T (1997) Chemoradiotherapy followed by surgery compared with surgery alone in squamous-cell cancer of the esophagus. N Engl J Med 337(3):161–167CrossRefPubMed
15.
go back to reference Visser BC, Venook AP, Patti MG (2003) Adjuvant and neoadjuvant therapy for esophageal cancer: a critical reappraisal. Surg Oncol 12(1):1–7CrossRefPubMed Visser BC, Venook AP, Patti MG (2003) Adjuvant and neoadjuvant therapy for esophageal cancer: a critical reappraisal. Surg Oncol 12(1):1–7CrossRefPubMed
16.
go back to reference Urschel JD, Vasan H (2003) A meta-analysis of randomized controlled trials that compared neoadjuvant chemoradiation and surgery to surgery alone for resectable esophageal cancer. Am J Surg 185(6):538–543CrossRefPubMed Urschel JD, Vasan H (2003) A meta-analysis of randomized controlled trials that compared neoadjuvant chemoradiation and surgery to surgery alone for resectable esophageal cancer. Am J Surg 185(6):538–543CrossRefPubMed
17.
go back to reference Kaklamanos IG, Walker GR, Ferry K, Franceschi D (2003) Neoadjuvant treatment for resectable cancer of the esophagus and the gastroesophageal junction: a meta-analysis of randomized clinical trials. Ann Surg Oncol 10:754–761CrossRefPubMed Kaklamanos IG, Walker GR, Ferry K, Franceschi D (2003) Neoadjuvant treatment for resectable cancer of the esophagus and the gastroesophageal junction: a meta-analysis of randomized clinical trials. Ann Surg Oncol 10:754–761CrossRefPubMed
18.
go back to reference Greer SE, Goodney PP, Sutton JE, Birkmeyer JD (2005) Neoadjuvant chemoradiotherapy for esophageal carcinoma:a meta-analysis. Surgery 137:172–177CrossRefPubMed Greer SE, Goodney PP, Sutton JE, Birkmeyer JD (2005) Neoadjuvant chemoradiotherapy for esophageal carcinoma:a meta-analysis. Surgery 137:172–177CrossRefPubMed
19.
go back to reference Gebski V, Burmeister B, Smithers BM, Foo K, Zalcberg J, Simes J (2007) Survival benefits from neoadjuvant chemoradiotherapy or chemotherapy in oesophageal carcinoma: a meta-analysis. Lancet Oncol 8:226–234CrossRefPubMed Gebski V, Burmeister B, Smithers BM, Foo K, Zalcberg J, Simes J (2007) Survival benefits from neoadjuvant chemoradiotherapy or chemotherapy in oesophageal carcinoma: a meta-analysis. Lancet Oncol 8:226–234CrossRefPubMed
20.
go back to reference Urba SG, Orringer MB, Turrisi A et al. (2001) Randomized trial of preoperative chemoradiation versus surgery alone in patients with locoregional esophageal carcinoma. J Clin Oncol 19:305–313PubMed Urba SG, Orringer MB, Turrisi A et al. (2001) Randomized trial of preoperative chemoradiation versus surgery alone in patients with locoregional esophageal carcinoma. J Clin Oncol 19:305–313PubMed
21.
go back to reference Berger AC, Farma J, Scott WJ et al. (2005) Complete response to neoadjuvant chemoradiotherapy in esophageal carcinoma is associated with significantly improved survival. J Clin Oncol 23:4330–4337CrossRefPubMed Berger AC, Farma J, Scott WJ et al. (2005) Complete response to neoadjuvant chemoradiotherapy in esophageal carcinoma is associated with significantly improved survival. J Clin Oncol 23:4330–4337CrossRefPubMed
22.
go back to reference Saito R, Suzuki H, Motoyama S, Sasaki S, Okuyama M, Ogawa J, Kitamura M (2000) A clinical study of surgical treatment of patients with carcinoma of the cervical esophagus extending to the thoracic esophagus. Jpn J Thorac Cardiovasc Surg 48(7):417–423PubMed Saito R, Suzuki H, Motoyama S, Sasaki S, Okuyama M, Ogawa J, Kitamura M (2000) A clinical study of surgical treatment of patients with carcinoma of the cervical esophagus extending to the thoracic esophagus. Jpn J Thorac Cardiovasc Surg 48(7):417–423PubMed
23.
go back to reference Peracchia A, Bonavina L, Botturi M, Pagani M, Via A, Saino G (2001) Current status of surgery for carcinoma of the hypopharynx and cervical esophagus. Dis Esoph 14:95–97CrossRef Peracchia A, Bonavina L, Botturi M, Pagani M, Via A, Saino G (2001) Current status of surgery for carcinoma of the hypopharynx and cervical esophagus. Dis Esoph 14:95–97CrossRef
24.
go back to reference Liebermann-Meffert DM, Luescher U, Neff U, Rüedi TP, Allgöwer M (1987) Esophagectomy without thoracotomy: is there a risk of intramediastinal bleeding? A study on blood supply of the esophagus. Ann Surg 206(2):184–192PubMedCrossRef Liebermann-Meffert DM, Luescher U, Neff U, Rüedi TP, Allgöwer M (1987) Esophagectomy without thoracotomy: is there a risk of intramediastinal bleeding? A study on blood supply of the esophagus. Ann Surg 206(2):184–192PubMedCrossRef
25.
go back to reference Stahl M, Stuschke M, Lehmann N, Meyer HJ, Walz MK, Seeber S, Klump B, Budach W, Teichmann R, Schmitt M, Schmitt G, Franke C, Wilke H (2005) Chemoradiation with and whitout surgery in patients with locally advanced squamous cell carcinoma of the esophagus. J Clin Oncol 23(10):2310–2317CrossRefPubMed Stahl M, Stuschke M, Lehmann N, Meyer HJ, Walz MK, Seeber S, Klump B, Budach W, Teichmann R, Schmitt M, Schmitt G, Franke C, Wilke H (2005) Chemoradiation with and whitout surgery in patients with locally advanced squamous cell carcinoma of the esophagus. J Clin Oncol 23(10):2310–2317CrossRefPubMed
26.
go back to reference Bedenne L, Michel P, Bouche O et al. (2002) Randomised phase III trial in locally advanced esophageal cancer: Radiochemotherapy followed by surgery versus radiochemotherapy alone (FFCD 9102). Proc Am Soc Clin Oncol 21:130a abstr 519 Bedenne L, Michel P, Bouche O et al. (2002) Randomised phase III trial in locally advanced esophageal cancer: Radiochemotherapy followed by surgery versus radiochemotherapy alone (FFCD 9102). Proc Am Soc Clin Oncol 21:130a abstr 519
27.
go back to reference Burmeister B, Dickie G, Smithers B, Hodge R, Morton K (2000) Thirty-four patients with carcinoma of the cervical esophagus treated with chemoradiation therapy. Arch Otolaryngol Head Neck Surg 126:205–208PubMed Burmeister B, Dickie G, Smithers B, Hodge R, Morton K (2000) Thirty-four patients with carcinoma of the cervical esophagus treated with chemoradiation therapy. Arch Otolaryngol Head Neck Surg 126:205–208PubMed
Metadata
Title
Chemo-radiotherapy in Locally Advanced Squamous Cell Oesophageal Cancer—are Upper Third Tumours more Responsive?
Authors
Andras Papp
Laszlo Cseke
Robert Farkas
Gabor Pavlovics
Gabor Horvath
Gabor Varga
Andras Szigeti
Szabolcs Bellyei
Sandor Marton
Laszlo Poto
Katalin Kalmar
Andras Vereczkei
Eva Pozsgai
Ors Peter Horvath
Publication date
01-06-2010
Publisher
Springer Netherlands
Published in
Pathology & Oncology Research / Issue 2/2010
Print ISSN: 1219-4956
Electronic ISSN: 1532-2807
DOI
https://doi.org/10.1007/s12253-009-9206-5

Other articles of this Issue 2/2010

Pathology & Oncology Research 2/2010 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine